Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 21, 2015 7:33 PM ET

Biotechnology

Company Overview of Xencor, Inc.

Company Overview

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases; XmAb7195, an IgE inhibitor that is in Phase Ib clinical trials initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate, which is in Phase II clinical t...

111 West Lemon Avenue

Monrovia, CA 91016

United States

Founded in 1997

37 Employees

Phone:

626-305-5900

Fax:

626-305-0350

Key Executives for Xencor, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 44
Total Annual Compensation: $363.7K
Chief Medical Officer
Age: 60
Total Annual Compensation: $322.5K
Chief Business Officer
Age: 55
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.

Xencor, Inc. Key Developments

Xencor, Inc. Appoints A. Bruce Montgomery, M.D as Director

Effective as of March 18, 2015, the Board of Directors of Xencor, Inc. appointed A. Bruce Montgomery, M.D. as a director of the company.

Xencor, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:30 PM

Xencor, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: John J. Kuch, Principal Financial Officer, Principal Accounting Officer and Vice President of Finance.

Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Xencor, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $1,350,000 compared to $3,703,000 a year ago. Revenues were $5,664,000 against $1,745,000 a year ago. Loss from operations was $1,350,000 against $3,710,000 a year ago. For the year, the company reported net loss of $16,422,000 compared to $60,259,000 a year ago. Fully diluted net loss per share was $0.52 compared to $3.85 a year ago. Revenues were $9,520,000 against $10,172,000 a year ago. Loss from operations was $16,457,000 against $10,520,000 a year ago.

Similar Private Companies By Industry

Company Name Region
BioDisplay Technologies, Inc. United States
Primorigen Biosciences Inc. United States
PolaRx Biopharmaceuticals, Inc. United States
Vedantra Pharmaceuticals, Inc. United States
Dermatrends, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Xencor, Inc., please visit www.xencor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.